Podoplanin (PDPN) is a mucin-like transmembrane glycoprotein that plays an important role in development and cancer. Here, we provide evidence that the intracellular domain (ICD) of podoplanin is released into the cytosol following a sequential proteolytic processing by a metalloprotease and -secretase. Western blotting and cell fractionation studies revealed that HEK293T and MDCK cells transfected with an eGFP-tagged podoplanin construct (PDPNeGFP,(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63) constitutively express two C-terminal fragments (CTFs): a ~3 3 kDa membrane-bound PCTF33, and a ~2 9 kDa cytosolic podoplanin ICD (PICD). While pharmacological inhibition of metalloproteases reduced the expression of PCTF33, treatment of cells with -secretase inhibitors resulted in enhanced PCTF33 levels. PCTF33 processing by -secretase depends on presenilin-1 (PS1) function: cells expressing a dominant negative form of PS1 (PS1 D385N), and mouse embryonic fibroblasts (MEFs) genetically deficient in PS1, but not in PS2, show higher levels of PCTF33 expression with respect to wild-type MEFs. Furthermore, transfection of PS1 deficient MEFs with wild-type PS1 (PS1 wt) decreased PCTF33 levels. N-terminal amino acid sequencing of the affinity purified PICD revealed that the -secretase cleavage site was located between valines 150 and 151, but these residues are not critical for proteolysis. We found that podoplanin CTFs are also generated in cells expressing podoplanin mutants harboring heterologous transmembrane regions. Taken together, these results indicate that podoplanin is a novel substrate for PS1/-secretase.
Introduction
Podoplanin (PA2.26 antigen, Aggrus, T1) is a small mucin-like transmembrane glycoprotein that functions both as a cell adhesion molecule (Cueni and Detmar, 2009; Kato et al., 2003; Tsuneki et al., 2013) and a promoter of cell migration/invasion (Martín-Villar et al., 2006; Scholl et al., 1999; Wicki et al., 2006) . It is expressed in several normal cell types and tissues, such as the alveolar epithelium, mesothelia and lymphatic vessels (Schacht et al., 2005; Wicki and Christofori, 2007) . Studies with podoplanin-deficient mice suggest that this glycoprotein is involved in lung morphogenesis, lymphatic vasculature formation, and cardiac development (Mahtab et al., 2008 (Mahtab et al., , 2009 Ramirez et al., 2003; Schacht et al., 2003) . Podoplanin expression is upregulated in a variety of cancers, including squamous cell carcinomas and glioblastomas, where it is associated with malignant progression and metastasis ( Astarita et al., 2012; Wicki and Christofori, 2007) .
Podoplanin is composed of three structural domains: a highly O-glycosylated extracellular (EC) domain; a hydrophobic transmembrane (TM) domain; and a 9 amino acid-long cytoplasmic (CT) tail that lacks any evident enzymatic motif (Kaneko et al., 2004; Martín-Villar et al., 2005; Scholl et al., 1999) . A fraction of podoplanin is localized in detergent-resistant membrane domains or raft platforms (Barth et al., 2010; Fernández-Muñoz et al., 2011) . Our laboratory has also demonstrated that recruitment of podoplanin to these structures requires both the TM and CT domains and, more importantly, that the function of podoplanin is affected by its exclusion from them (Fernández-Muñoz et al., 2011) .
Podoplanin binding to ezrin and moesin of the ERM (ezrin, radixin, moesin) protein family links the CT domain of podoplanin to the actin cytoskeleton, which leads to the activation of small Rho GTPases and to the induction of cell migration/invasion and epithelial-mesenchymal transition (Martín-Villar et al., 2006; Navarro et al., 2008; Scholl et al., 1999; Wicki et al., 2006) . In addition, podoplanin can induce platelet aggregation by interacting with the C-type lectin-like receptor 2 (CLEC-2). This process is important for physiological and pathological events, like the differentiation of the lymphatic vasculature from the blood vascular system (Uhrin et al., 2010) , the maintenance of high endothelial venules integrity in lymph nodes during immune responses (Herzog et al., 2013) , or podoplanin-mediated pulmonary metastasis of tumor cells (Kunita et al., 2007; Nakazawa et al., 2008) . Finally, the interaction of podoplanin with the hyaluronan receptor CD44 seems crucial for podoplanin-dependent stimulation of directional migration in carcinoma cells (Martín-Villar et al., 2010) as well as for tethering tumor cells to hyaluronan-rich extracellular matrices (Tsuneki et al., 2013) .
Proteolytic processing of membrane glycoproteins regulates their stability and also plays a crucial role in the regulation of their function and signaling properties (Cullen, 2011; Haapasalo and Kovacs, 2011) . In particular, cleavage within the hydrophobic TM domain, or regulated intramembrane proteolysis (RIP), is a process that has emerged as an important mechanism regulating key cellular events, including adhesion and migration (Beel and Sanders, 2008; Haapasalo and Kovacs, 2011) . In order to be able to detect the existence of both N-and C-terminal fragments, we used a human podoplanin construct fused to the enhanced green fluorescent protein (PDPNeGFP), given that no available podoplanin antibody reacts with the CT tail of the protein.
Previous results from our laboratory showed that the use of a C-terminal eGFP tag does not affect podoplanin subcellular localization and function (Martín-Villar et al., 2005 . We report here that a metalloprotease-dependent cleavage of podoplanin generates a membrane-bound C-terminal stub that is further processed by PS1/-secretase, thus releasing the intracellular domain of podoplanin (PICD) into the cytosol.
Materials and methods

Antibodies and reagents
The human podoplanin monoclonal antibody (mAb) NZ1 was from Acris Antibodies.
We used a GFP mAb from Roche for Western blotting, and a rabbit polyclonal antibody from Molecular Probes for GFP-affinity purification of PICD. The P 37-51 peptide has been previously described (Martín-Villar et al., 2005) . Horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG was from Amersham and HRP-conjugated goat antirat IgG from Pierce. The metalloprotease inhibitors GM6001 and Marimastat were from Calbiochem; all other inhibitors were from Sigma-Aldrich.
Constructs
The PDPNeGFP plasmid has been described elsewhere (Martín-Villar et al., 2005) .
The PDPN-RQ* construct was obtained from the PDPNeGFP plasmid that was previously modified to introduce a silent AccI site at position S 127 (Fernández-Muñoz et al., 2011) . AccI digestion of this plasmid was followed by blunting with the Klenow fragment of DNA polymerase I and re-ligation. The internal addition of two nucleotides resulted in a frameshift after S 127 that introduced a two-amino acid mutation followed by a premature stop codon. mM NaCl) plus protease and phosphatase inhibitors (2 mM PMSF, 2 g/ml leupeptin, 2 g/ml aprotinin, 0.1 mM sodium orthovanadate, 2 mM -glycerophosphate, and 1 mM NaF). In order to obtain PDPNeGFP-HEK293 stable transfectants for affinity purification of PICD, cells were transfected as indicated above and cultured in complete medium supplemented with 500 µg/ml G418 for three weeks.
Cell fractionation and preparation of conditioned medium
Cytosolic and membrane fractions were obtained according to the online protocol by Abcam. Briefly, cells grown in P100 dishes were lysed in ice-cold subcellular fractionation buffer (250 mM sucrose, 20 mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT) with protease and phosphatase inhibitors. Cells were scraped, passed ten times through a 25 G needle, and incubated 20 min on ice. The lysate was centrifuged at 720 g for 5 min and the supernatant centrifuged for 10 min at 10 000 g. The cytosolic (supernatant) and membrane (pellet) fractions were obtained by centrifugation of the resulting supernatant at 100 000 g for 1 h. The membrane fraction was washed once with fractionation buffer and centrifuged for 45 min at 100 000 g. Conditioned medium of PDPNeGFP-MDCK cell transfectants was obtained by culturing confluent P150 plates in serum-free medium for 24 h, cleared by centrifugation at 1 500 rpm for 5 min, and concentrated by precipitation with 4 volumes of cold acetone at -20⁰C for 1 h. The precipitated proteins were pelleted by centrifugation at 14 000 g for 20 min. The membrane fraction and precipitated conditioned medium pellets were resuspended in RIPA buffer and centrifuged to remove insoluble material at 13 000 g. All centrifugations were carried out at 4⁰C.
Gel electrophoresis and Western blotting
Electrophoresis in 10% or 12% acrylamide gels and Western blot analysis were performed as previously described (Martín-Villar et al., 2005) . For determining band specificity, NZ1 was pre-incubated with the P 37-51 peptide 30 min prior to blotting the membrane. Peroxidase activity was detected with the enhanced chemiluminescence kit (Amersham).
Affinity purification of the PICD fragment and amino acid sequencing
Affinity purification of PICD from the cytosolic fraction of cells stably expressing In order to further analyze the nature of these fragments, we studied their subcellular distribution. To that effect, we obtained membrane and cytosolic fractions of MDCK-PDPNeGFP and MDCK-eGFP stable transfectants, and analyzed the expression of the different polypeptides by Western blotting (Fig. 1B) . As expected, the 60-63 and ~4 8 kDa bands corresponding to fl-PDPN were found exclusively in the membrane fraction. In addition, PCTF27 (~27 kDa), PCTF33 (~33 kDa), and the 37-45 kDa N-terminal polypeptide were also found in this fraction (Fig. 1B middle and right panels), suggesting that they either retain the TM domain or remain associated to a membrane component. On the other hand, the ~2 9 kDa CTF was detected exclusively in the cytosolic fraction (Fig. 1B, middle panel) . This fragment contains only a small portion of the C-terminal region of podoplanin since the eGFP tag has an apparent molecular mass of 27 kDa (Fig. 1B, left panel) . Given that the ICD of podoplanin is 9 amino acid-long, the soluble 29 kDa fragment most likely corresponds to the entire ICD of podoplanin fused to the eGFP tag (PICD).
Podoplanin EC domain cleavage by a metalloprotease yields PCTF33
Two alternative mechanisms may account for the formation of the newly identified PICD: the existence of an alternative translation initiation site in podoplanin's mRNA, as has been described for the tyrosine kinase receptor HER2 (Anido et al., 2006) ; or through RIP, as is the case for the Alzheimer's disease-associated amyloid precursor protein and Notch1 (De Strooper et al., 1999; Xia and Wolfe, 2003) . Besides methionine at position 1, human podoplanin contains three additional internal methionines: at positions 43, 153 and 156 in the EC, TM and CT domains, respectively (Martín-Villar et al., 2005) . In order to test the first hypothesis, we used a truncated podoplanin construct, PDPN-RQ*, which contains a frameshift mutation that introduces a premature stop codon two amino acids downstream of S 127 in the EC domain of podoplanin ( Fig.2A, right) . Expression of PDPN-RQ* is expected to produce a podoplanin N-terminal fragment detectable with NZ1 but not with anti-GFP Ab. Smaller GFP-tagged polypeptides would not be detected unless internal methionines could act as alternative translation initiation sites. Transfection of PDPN-RQ* in HEK293T cells yielded a ~4 0 kDa polypeptide that was detected with NZ1 ( Fig. 2A, left blot) .
Importantly, no polypeptide was detected with the anti-GFP Ab ( Fig.2A, middle blot) .
Thus, podoplanin CTFs are not produced by initiation of translation at alternative sites, but are derived from fl-PDPN ( Fig. 2A, right blot) .
In order to confirm that the observed CTFs are indeed the products of fl-PDPN proteolytic processing, we treated HEK293T cells transiently expressing PDPNeGFP with a panel of broad spectrum protease inhibitors. This panel included inhibitors that covered all five major protease families: aminopeptidases (bestatin), serine-(aprotinin), cystein-(E-64), aspartyl-(pepstatin), and metallo-(GM6001 and Marimastat)
proteases. Whereas none of the inhibitors significantly affected the amount of fl-PDPN, we observed a clear reduction in the levels of PCTF33 in cells treated with the two metalloprotease inhibitors (Fig. 2B) . The 37-45 kDa N-terminal fragment, on the other hand, was not downregulated by metalloprotease inhibitor treatment (data not shown).
We also observed a significant accumulation of PCTF33 in cells treated with pepstatin, suggesting that this fragment is further processed by an aspartyl-protease. The proteolytic processing we describe here is reminiscent of RIP, which is usually preceded by a shedding event close to the TM domain of the substrate protein that releases the EC domain into the extracellular medium (Beel and Sanders, 2008; Sannerud and Annaert, 2009) . We then analyzed the conditioned medium of MDCK cells expressing PDPNeGFP for the presence of a soluble podoplanin N-terminal fragment. Interestingly, we not only were unable to detect a soluble podoplanin EC fragment, but we observed the same band pattern in the cell lysate and the conditioned medium (Fig. 2C) . Preliminary results from our laboratory indicate that this is due to the fact that podoplanin is being released into the conditioned medium associated to exosomes (Carrasco-Ramirez et al., unpublished results). Therefore, PCTF33 is generated by a metalloprotease-dependent cleavage within the EC domain of fl-PDPN.
However, we have not been able to detect the resulting soluble EC domain fragment in the exosome-free conditioned medium, suggesting that it is probably being rapidly degraded.
PCTF33 is a substrate of -secretase
The proteolytic release of type I transmembrane protein ICDs into the cytosol is carried out by the members of one of two families of intramembrane cleaving proteases: the serine-protease rhomboid or the aspartyl-protease -secretase (Boulton et al., 2008; Xia and Wolfe, 2003) . While the former cleaves intact substrates, the latter uses as substrates C-terminal transmembrane stubs produced by cleavage of the EC domain.
Several observations suggested that podoplanin is probably a -secretase substrate: it is a type I transmembrane protein that is cleaved on its EC domain by a metalloprotease; the resulting membrane-bound PCTF33 fragment is further processed by an aspartyl-protease; and, finally, the PICD fragment is being released into the cytosol. To test this hypothesis, we treated HEK293T cells transiently transfected with PDPNeGFP with two different and highly specific -secretase inhibitors. The specific pharmacological inhibition of -secretase resulted in the accumulation of this fragment with no significant changes in fl-PDPN levels, indicating that PCTF33 is a substrate of -secretase (Fig. 3A) .
-secretase is a multisubunit enzyme complex that requires at least four proteins to be functional: presenilin (PS), nicastrin, Aph-1, and Pen-2 (Edbauer et al., 2003; Kimberly et al., 2003) . The catalytic subunit of the protease is one of the two known isoforms of PS: PS1 or PS2. Therefore, we studied whether PCTF33 cleavage by -secretase is dependent on PS activity. As a first approach, we transfected PDPNeGFP into HEK293 cells that stably express exogenous PS1 wt or the dominant negative PS1 D385N (Capell et al., 2000) . At similar levels of fl-PDPN expression (Fig. 3B , upper panel), co-expression of podoplanin with PS1 D385N led to a pronounced accumulation of PCTF33 (Fig. 3B, lower panel) . Similarly, when PDPNeGFP was transfected into PS1, PS2, or double PS1/PS2 knockout MEFs (Herreman et al., 1999 (Herreman et al., , 2003 , we observed an accumulation of PCTF33, even though the levels of exogenous fl-PDPN expression were similar in all cell lines. This accumulation was more pronounced in PS1 -/-and PS1/2 -/-than in PS2 -/-MEFs (Fig. 3C, second panel) , indicating that PS1 is the major PS isoform involved in PCTF33 cleavage. Furthermore, PCTF33 levels were reduced in wild-type and PS-deficient MEFs co-transfected with PDPNeGFP and PS1 wt (Wolfe et al., 1999) relative to MEFs transfected only with PDPNeGFP (Fig. 3C , compare second and bottom panels). These results confirm that PCTF33 is a PS1-dependent -secretase substrate.
PDPN is cleaved by -secretase between V
150 and V
151
The vast majority of -secretase substrates are cleaved at or very close to the boundary of the TM and CT domains, but a consensus sequence has not been identified (Haapasalo and Kovacs, 2011) . However, the -secretase cleavage site usually flanks a sequence rich in lysine and/or arginines. The TM and CT domains of podoplanin are well conserved across species and contain three highly conserved lysine and arginine residues in the juxtamembrane region (Fig. 4A, underlined) .
Another common feature of many -secretase substrates is the presence of a valine close to the membrane-cytosol interface that lies immediately to the right of the cleavage site (Fig. 4B) . Furthermore, mutation of this residue can abrogate proteolysis by -secretase in some substrates, including Notch (Huppert et al., 2000) and ErbB4 (Vidal et al., 2005) . The TM domain of podoplanin possesses several conserved valine residues in that region ( Fig. 4A and B, shaded) . N-terminal sequencing of the affinity purified PICD fragment by Edman degradation yielded the sequence VVMXKM, indicating that the -secretase cleavage site is located between V 150 and V 151 within the TM domain of podoplanin (Fig. 4B) . However, mutation of these residues to phenylalanine did not prevent the formation of CTFs (data not shown). In addition, we analyzed the expression of PCTF33 in MDCK cells expressing one of three previously described podoplanin constructs: PDPN-ECD, PDPN-CD45 and PDPN-TLR9 (Fernández-Muñoz et al., 2011) . In these constructs, the TM domain of podoplanin was replaced by that of E-cadherin, the leukocyte common antigen CD45, or the Toll-like receptor TLR9, respectively (Fig. 4C ). As shown in Fig. 4C , both PDPN-ECD and PDPN-CD45 constitutively produced a 33 kDa CTF. The levels of this CTF diminished upon metalloprotease inhibitor treatment and accumulated following DAPT treatment, indicating that it is produced by the action of a metalloprotease and that it is a substrate of -secretase. Both CD45 and E-cadherin have been previously identified as -secretase substrates (Kirchberger et al., 2008; Marambaud et al., 2002) . In contrast,
we did not observe the formation of CTFs in cells expressing PDPN-TLR9. In contrast to the other two TM chimera, most of PDPN-TLR9 does not reach the cell surface but is retained in cytoplasmic intracellular vesicles (Fernández-Muñoz et al., 2011) . The function of -secretase is tightly regulated by intracellular transport of its components and substrates (Sannerud and Annaert, 2009 ). Thus, the localization of the PDPN-TLR9 chimera would prevent it from being processed first by the metalloprotease and then by -secretase. Finally, localization in lipid rafts can promote -secretase processing of some substrates, including the amyloid precursor protein (Cheng et al., 2007 ). Podoplanin has been described to associate with lipid rafts (Barth et al., 2010; Fernández-Muñoz et al., 2011) . However, podoplanin localization in these microdomains is not necessary for PS1/-secretase processing, since the TM chimeras PDPN-ECD and PDPN-CD45, which are cleaved by -secretase, have been shown to be excluded from lipid rafts (Fernández-Muñoz et al., 2011) .
Biological implications of PDPN cleavage
In summary, our results demonstrate that podoplanin undergoes a sequential proteolytic processing that leads to the liberation of its intracellular domain (PICD) into the cytosol. In a first step, a metalloprotease cleaves podoplanin on its EC domain (Fig.   5, step 1) . The metalloprotease-dependent cleavage of podoplanin generates a membrane-anchored C-terminal fragment that has an apparent molecular weight of approximately 33 kDa when fused to the eGFP tag (PCTF33). Podoplanin EC domain cleavage most probably occurs at the plasma membrane, since no CTF is formed when cells express a podoplanin TM chimera that does not reach the plasma membrane, PDPN-TLR9. We have not been able to detect the EC domain fragment resulting from metalloprotease cleavage of podoplanin, raising the possibility that this fragment is being rapidly degraded. In addition to PCTF33, we have detected two other membrane-associated podoplanin fragments: a C-terminal fragment of approximately 27 kDa (PCTF27) and a 37-45 kDa N-terminal fragment. These additional fragments probably arise from independent alternative proteolytic processing events that occur simultaneously to the sequential processing that we describe here. We have previously reported that podoplanin is a substrate of calpain-1 (Martín-Villar et al., 2009).
However, calpain-1 leads to the complete degradation of podoplanin, and the fragments described here co-exist with fl-PDPN, suggesting that this protease is not involved in their generation.
Finally, we demonstrate that the membrane-anchored PCTF33 fragment is further processed by -secretase, and that this process, which is dependent on PS1 activity, results in the release of a short PICD into the cytosol (Fig. 5, step 2) . The ICDs of some of -secretase substrates have been shown to function as signaling molecules.
This is the case of the amyloid precursor protein, Notch and CD44 (Beckett et al., 2012; Nagano and Saya, 2004) , whose intracellular domains, when released by -secretase cleavage, are targeted to the nucleus where they regulate gene expression.
In contrast, the ICDs of other -secretase substrates, like MUC1, are rapidly degraded (Julian et al., 2009 ). Indeed, it has been suggested that -secretase may function as the membrane proteasome (Kopan and Ilagan, 2004) . The intracellular domain of podoplanin is extremely short and, therefore, would be expected to readily enter the nucleus. However, the release of a transmembrane protein ICD that functions as a signaling molecule would be expected to be a highly regulated event (Kopan and Ilagan, 2004) . Our results indicate that the proteolytic processing of podoplanin does not occur in response to an external signal, but is constitutive. This suggests that - 
